BIJUVE (Estradiol and Progesterone combined)

Clinical Indication

Indicated for continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.

Date of classification

May 2024


Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.